{"symbol":"LLY","fiscalQuarter":"Q2-2020","reportDate":"2020-07-30","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q2-2020","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Down 5.4%","keyNumbers":[{"metric":"EPS","actual":"$1.89","expected":"N/A","surprise":"+19.62%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative treatments to patients."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, no specific guidance was provided for future performance."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Eli Lilly's strong EPS performance indicates effective cost management and operational efficiency. However, the stock fell by 5.4% following the earnings report, likely due to the lack of revenue details and forward guidance, which may have left investors uncertain about future growth prospects.","metaDescription":"Eli Lilly (LLY) Q2 2020 earnings: EPS beat by 19.62%. Stock down 5.4%. Full breakdown."}}